The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio ® is a ...

The 5th Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) will gather industry leaders in Vösendorf, Austria on ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

Shares of 3SBio jumped as much as 52% in Hong Kong, the most on record, extending gains for the third consecutive session.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

CEOs are yet to collectively, and definitively, stand up to President Donald Trump's attacks against businesses.

Chris Toomey, Morgan Stanley managing director of private wealth, said in a latest program on CNBC that he is not bullish on stocks yet and plans to “stay defensive” until a few key issues are ...

Merck & Co – known as MSD outside the US and Canada – has received approval from the Medicines and Healthcare products ...

Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Merck Animal Health is investing $895 million in a De Soto new facility, which will bring hundreds of jobs. It’s a huge economic investment for the company, and the small town.